You’ve built the innovation. Now let’s build the business.
Healthcare is littered with superior products that never reached the patients who needed them most.
Founders and innovation teams spend years and millions in capital perfecting the technology, running clinical trials, and securing regulatory clearance. But when it finally comes time to launch, they hit a wall. They fall victim to the ultimate healthcare fallacy: "If we build a better product, the health system will buy it."
The reality is far more complex. A great product is not a scalable business. Moving from the R&D phase to full-scale commercialisation requires a massive shift in mindset and strategy. Here is what you need to build the business behind the innovation.
1. A health-specific business model
Standard SaaS or direct-to-consumer models rarely survive contact with a complex health system like the NHS or European multi-payer models. You need to understand how money actually flows. Who is the end-user? Who is the payer? Are there existing reimbursement codes you can leverage, or are you asking the hospital to carve out a brand-new budget? If your product doesn't fit neatly into an existing procurement pathway, your sales cycle will double in length.
2. An investor-ready business case
Investors in MedTech and HealthTech understand regulatory risks. What they want to see now is commercial viability. Your business case needs to move beyond total addressable market (TAM) fantasies. Investors want to see a concrete, milestone-driven go-to-market plan. They want to know your customer acquisition cost, your regulatory pathway, and exactly how you plan to win your first 10 paying enterprise customers and not just your revenue projections for year five.
3. Strategic positioning over reactive selling
When you launch, it is tempting to chase every single lead or pilot program that comes your way. This leads to exhausted teams and scattered resources. Scaling requires focus. It means knowing exactly which markets, which care pathways, and which specific clinical verticals offer the path of least resistance to adoption.
Case study: The HealthTech SaaS that chased every pilot
A digital remote patient monitoring startup had developed a brilliant, device-agnostic platform. Hungry for traction, they accepted pilots in cardiology, endocrinology (diabetes), and orthopaedics across four different hospital trusts.
Within eight months, the company was burning cash at an alarming rate. Because each clinical specialty required different software integrations, different patient onboarding workflows, and different regulatory compliance checks, the startup's engineering and sales teams were stretched to the breaking point. They had "traction," but none of it was scalable.
The pivot: We stepped in to provided an objective external market-facing and internal resource-concious perspective. We analysed the data and found that the cardiology pathway had the clearest existing reimbursement codes and the shortest sales cycle. We advised the founders to pause the other pilots and dedicate 100% of their limited resources to focusing on the cardiology niche. By standardising one specific go-to-market motion, their revenue stabilised, their operational costs plummeted, and they successfully attracted further funding.
Practical tips to transition from R&D to commercial growth
Define your "wedge": Don't try to boil the ocean. Find the narrowest, most painful problem your product solves for a specific buyer, and use that as your entry point into the system.
Build your commercial team early: Do not wait until your product is 100% perfect to start having commercial conversations. By the time you get regulatory clearance, you should already have a pipeline of stakeholders ready to initiate procurement.
Assess international markets properly: A product that works in the UK won't seamlessly drop into the German or UAE markets. Assess international expansion based on regulatory alignment and reimbursement pathways, not just population size.
Innovation keeps you afloat, but strategy gives you direction. Bridging the gap between a successful trial and market dominance requires knowing how health systems think and how growth companies need to operate. You've done the hard part by building the solution. Now, let's build the growth engine.